Frazier Management LLC Iovance Biotherapeutics, Inc. Transaction History

Frazier Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$12.38 - $19.1 $21.6 Million - $33.4 Million	-1,747,622 Closed	0 $0
Q4 2021 Feb 08, 2022	SELL	$16.55 - $27.63 $15.3 Million - $25.6 Million	-926,677 Reduced 34.65%	1,747,622 $33.4 Million
Q3 2021 Nov 12, 2021	BUY	$20.35 - $26.63 $10.9 Million - $14.3 Million	536,300 Added 25.08%	2,674,299 $65.9 Million
Q2 2021 Aug 11, 2021	BUY	$16.33 - $33.07 $13.5 Million - $27.3 Million	825,000 Added 62.83%	2,137,999 $55.6 Million
Q2 2020 Aug 04, 2020	SELL	$27.21 - $41.0 $11.9 Million - $17.9 Million	-437,666 Reduced 25.0%	1,312,999 $36 Million
Q3 2019 Nov 12, 2019	SELL	$17.99 - $26.0 $7.87 Million - $11.4 Million	-437,666 Reduced 20.0%	1,750,665 $31.9 Million
Q2 2017 Aug 14, 2017	BUY	N/A	2,188,331	2,188,331 $15.2 Million

313

237M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.18B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Frazier Management LLC, based on Form 13F filings with the SEC.

Stay updated on Frazier Management LLC with notifications on news.